Ofloxacin による複雑性尿路感染症の治療

Abstract

114例の複雑性尿路感染症例に対し, OFLX 600 mg/day, 分2ないし分3投与を行った.1) 114例の複雑性尿路感染症例のうち, 薬効を評価するうえでUTI基準を満たす者は67例(58.8%)であった.2)分離菌は101株存在したが, OFLXによる消失は82株(81.2%)であった.3)菌交代により新たに出現した菌株は20株で, そのうち6株はCandida sp.であった.4)総合臨床効果では著効率37.3%, 著効と有効をあわせた有効率は65.7%であった.5)副作用は114例中3例にみられたが, いずれも軽微であった

To study the treatment effects of ofloxacin (OFLX) on the patients with complicated urinary tract infections (UTI), OFLX at a daily dose of 600 mg divided into either two or three doses per day, was administered for 14 days to 114 patients with complicated UTI. Among the 114 patients, 67 patients satisfied the criteria for clinical evaluation of complicated UTI. One hundred and one organisms were isolated from these patients' urine. Among them, 82 organisms were eliminated following OFLX administration. Twenty organisms appeared newly by the replacement of organisms. Among them, 6 organisms belonged to Candida sp. As to the overall efficacy of OFLX, an excellent response was seen in 37.3% and sum of efficacy rate was 65.7%. Side effects were observed in 3 of the 114 patients. These results indicate that OFLX is both safe and effective enough to be used for the treatment of the patients associated with complicated UTI.